PMA device
Allegretto Wave Eye-Q Excimer Laser System
Alcon Laboratories, Inc. · Excimer Laser System (LZS, Class III) · First FDA decision Jun 16, 2006, newest May 1, 2015Nearsightedness and refractive error
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
3
Naming "Allegretto Wave Eye-Q"
MAUDE reports
3,960
Brand "Allegretto Wave Eye-Q", since 2015
PubMed studies
44
Mentioning "Allegretto Wave Eye-Q"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Allegretto Wave Eye-Q Excimer Laser System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- ALLEGRETTO WAVE EYE-Q EXCIMER LASER SYSTEMPMA supplement
P030008-S017 · Decided May 1, 2015 · 88 days after receipt · Normal 180 Day Track
Device type: Excimer laser system (LZS) · Ophthalmology
- ALLEGRETTO WAVE EYE-Q EXCIMER LASER SYSTEMPMA supplement
P030008-S003 · Decided Jun 16, 2006 · 441 days after receipt · Normal 180 Day Track
Device type: Excimer laser system (LZS) · Ophthalmology
- ALLEGRETTO WAVE EYE-Q EXCIMER LASER SYSTEMPMA supplement
P020050-S012 · Decided Sep 27, 2013 · 179 days after receipt · Panel Track
Device type: Excimer laser system (LZS) · Ophthalmology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Allegretto Wave Eye-Q", any status and sponsor, newest update first.
- A Safety and Effectiveness Study of PRK Using the ALLEGRETTO WAVE® EYE-Q Excimer Laser SystemCompleted
Alcon ResearchNot on our public-company list
NCT01699087 · 176 participants · Start Aug 2012 · Primary completion Jul 2015
Device: ALLEGRETTO WAVE EYE-Q excimer laser system · For: Myopia; Astigmatism
Clinical Research Consultants, Inc.Not on our public-company list
NCT01028378 · 212 participants · Start Oct 2009 · Primary completion Apr 2012
Device: T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser · For: Myopia; Hyperopia
Sites: La Quinta, California; San Diego, California; Atlanta, Georgia · 10 sites in all
Daniel S. Durrie, MDAcademic, hospital or other
NCT01746589 · 22 participants · Start Nov 2011 · Primary completion Jan 2012
Device: bilateral myopic LASIK · For: Myopia
Sites: Overland Park, Kansas
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Allegretto Wave Eye-Q", and for the whole product code for context.
This brand
3,960 reports: 331 malfunction, 3,629 injury, 0 death
Whole product code LZS
7,603 reports: 949 malfunction, 6,624 injury, 12 death
Newest reports for this brand
3003288808-2026-00106 · Received Feb 20, 2026
Device type: Excimer Laser System (LZS)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Visual Impairment
- ALLEGRETTO WAVE EYE-Q EXCIMER LASERMalfunction
3003288808-2025-00015 · Received Jan 21, 2025
Device type: Excimer Laser System (LZS)
Device problem as coded: Energy Output Problem
Patient problem as coded: Insufficient Information
- ALLEGRETTO WAVE EYE-Q EXCIMER LASERMalfunction
3003288808-2022-00271 · Received Nov 4, 2022
Device type: Excimer Laser System (LZS)
Device problem as coded: Failure to Capture
Patient problem as coded: Insufficient Information
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Allegretto Wave Eye-Q"[tiab]. The summary above synthesizes these.
- Wavefront-optimized laser in situ keratomileusis with the Allegretto Wave Eye-Q excimer laser and the FEMTO LDV Crystal Line femtosecond laser: 6 month visual and refractive results.
Ziaei M, Mearza AA, Allamby D · Cont Lens Anterior Eye · 2015Comparative Study, Controlled Clinical Trial
- A prospective, randomized, fellow eye comparison of WaveLight® Allegretto Wave ® Eye-Q versus VISX CustomVueࡊ STAR S4 IRࡊ in laser in situ keratomileusis (LASIK): analysis of visual outcomes and higher order aberrations.
Moshirfar M, Betts BS, Churgin DS, et al. · Clin Ophthalmol · 2011
- One-year follow-up of patients with hyperopia undergoing photorefractive keratectomy with Allegretto WaveLight Eye Q 400.
Shahin B, Ojaghi H, Amani F · J Med Life · 2022
- Prospective, randomized, fellow eye comparison of WaveLight Allegretto Wave Eye-Q versus VISX CustomVueTM STAR S4 IRTM in photorefractive keratectomy: analysis of visual outcomes and higher-order aberrations.
Moshirfar M, Churgin DS, Betts BS, et al. · Clin Ophthalmol · 2011
- Wavefront-optimized surface ablation with the Allegretto Wave Eye-Q excimer laser platform: 12-month visual and refractive results.
Gambato C, Catania AG, Vujosevic S, et al. · J Refract Surg · 2011
- Visual and refractive outcomes of LASIK with the SCHWIND ESIRIS and WaveLight ALLEGRETTO WAVE Eye-q excimer lasers: a prospective, contralateral study.
Mearza AA, Muhtaseb M, Aslanides IM · J Refract Surg · 2008Comparative Study
- Photorefractive keratectomy for myopia and myopic astigmatism correction using the WaveLight Allegretto Wave Eye-Q excimer laser system.
Costa E, Franqueira N, Rosa AM, et al. · Int Ophthalmol · 2014
- Investigation of the Changes in Refractive Surgery Trends in Korea.
Ahn JH, Kim DH, Shyn KH · Korean J Ophthalmol · 2018
- Irregular Astigmatism After Corneal Transplantation--Efficacy and Safety of Topography-Guided Treatment.
Laíns I, Rosa AM, Guerra M, et al. · Cornea · 2016
- Sutureless cryopreserved amniotic membrane graft and wound healing after photorefractive keratectomy.
Vlasov A, Sia RK, Ryan DS, et al. · J Cataract Refract Surg · 2016Controlled Clinical Trial
- Quality of life and satisfaction among physicians after wavefront-optimized vs topography-guided laser vision correction.
Ma J, Pillar A, Krueger R · J Cataract Refract Surg · 2020
- Wavefront-guided versus wavefront-optimized photorefractive keratectomy: Clinical outcomes and patient satisfaction.
Sia RK, Ryan DS, Stutzman RD, et al. · J Cataract Refract Surg · 2015Comparative Study, Randomized Controlled Trial
Other devices of this type
Also filed under product code LZS.
- WaveLight EX500 LaserAlcon Laboratories, Inc. · PMA 2025
- Wavelight Allegretto Wave Excimer Laser SystemAlcon Laboratories, Inc. · PMA 2013
- STAR S4 IR Excimer Laser System and iDESIGN Refractive StudioAmo Manufacturing USA, LLC · PMA 2019
- Nidek EC-5000 Excimer Laser SystemNidek Co., Ltd. · PMA 2018
- Bausch & Lomb Technolas T217Z Zyoptix Laser SystemTechnolas Perfect Vision GmbH · PMA 2010
- Ladarvision 4000 Excimer Laser System and the Ladar 6000 Excimer Laser SystemAlcon Laboratories · PMA 2006
- Technolas 217A Excimer Laser SystemTechnolas Perfect Vision GmbH · PMA 2003
- iDESIGN Refractive Studio, STAR S4 IR Excimer Laser SystemAmo Manufacturing USA, LLC · PMA 2024
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.